" class="no-js "lang="en-US"> Stanley C. Erck Archives - Pharmtech Focus
Friday, January 27, 2023

Breaking News

Kinnate Biopharma Adds Global Business and Oncology Expertise to Board of Directors Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication New AI Tool Makes Speedy Gene Editing Possible European Medicines Agency accepts Marketing Authorization Application for lecanemab as treatment for early Alzheimer’s disease Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO Chews for Dogs Sharecare Launches VR Program to Improve Well-being of American Workforce Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer Nogra Pharma Announces Out-licensing Agreement with Torii Pharmaceutical for Japan for New Chemical Entity Topical Acne Treatment Cerebral Therapeutics Names Julie Foster as Chief Operating Officer

Sort by:

Date

Top Post

ProPharma Acquires UK Based Digital Lab Consulting | PTF

ProPharma Acquires UK Based Digital Lab Consulting

ProPharma Group (ProPharma) the leading global provider of regulatory, clinical, and quality services for the […]

Read more

COVID-19

 U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine | Pharmtech Focus

U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious […]

COVID-19

 Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over | Pharmtech Focus

Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over

Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious […]

COVID-19

 Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom | Pharmtech Focus

Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious […]

Diseases

 Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases | Pharmtech Focus

Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious […]

COVID-19

 Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 Million Doses of COVID-19 Vaccine | Pharmtech Focus

Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 Million Doses of COVID-19 Vaccine

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today […]

Clinical Trials

 Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial | Pharmtech Focus

Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

Novavax, Inc. (Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% […]

COVID-19

 Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility | Pharmtech Focus

Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced […]

  1. Kinnate Biopharma Adds Global Business and Oncology Expertise to Board of Directors

    Appointments

     Read more
  2. Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication

    Diseases

     Read more
  3. New AI Tool Makes Speedy Gene Editing Possible

    Diseases

     Read more
  4. European Medicines Agency accepts Marketing Authorization Application for lecanemab as treatment for early Alzheimer’s disease

    Diseases

     Read more
  5. Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

    Diseases

     Read more